Open an account

Bioasis Technologies

BIOAF · TSX

$0.0001+$0.00 (+0.00%)TodayMarket closed ·
No price history for this range.

About BIOAF

biOasis Technologies, Inc. operates as a biopharmaceutical company. The company is headquartered in New Haven, Connecticut. The company went IPO on 2007-07-24. The firm is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). The company is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The firm is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

Employees
0
Headquarters
New Haven, Connecticut
Listed
Jul 24, 2007
Sector
Health Care
Industry
Biotechnology
Website
bioasis.us

BIOAF key statistics

Market cap
10.00K
Price-earnings ratio
—
Dividend yield
—
Average volume
46.86K
Volume
6.00K
Open price
$0.0001
High today
$0.0001
Low today
$0.0001
52 Week high
$0.0001
52 Week low
$0.00

Bioasis Technologies (BIOAF) at a glance

Bioasis Technologies (BIOAF) last traded at $0.0001, with a market cap of 10.00K.

Volume so far is 6.00K shares, below the average of 46.86K shares a day.

Over the past year Bioasis Technologies has ranged from $0.00 to $0.0001, and now sits 100% of the way up that range.

Bioasis Technologies met or beat analyst EPS estimates in 8 of the last 8 quarters. In Q3 FY23 it reported -$0.01 per share against an estimate of -$0.0103.

BIOAF earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 8 of the last 8 quarters, by 69.7% on average.

  1. Q2 FY15: reported -$0.02 per share against an estimate of -$0.0412
  2. Q2 FY21: reported $0.03 per share against an estimate of -$0.0103
  3. Q3 FY21: reported -$0.01 per share against an estimate of -$0.0103
  4. Q4 FY21: reported -$0.01 per share against an estimate of -$0.0206
  5. Q2 FY22: reported -$0.01 per share against an estimate of -$0.0103
  6. Q3 FY22: reported -$0.02 per share against an estimate of -$0.0206
  7. Q4 FY22: reported -$0.01 per share against an estimate of -$0.0206
  8. Q3 FY23: reported -$0.01 per share against an estimate of -$0.0103

Similar companies

Companies in the same industry as Bioasis Technologies

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.